

# Clinical characteristics and progression of COVID-19 confirmed cases admitted to a single British clinical centre—a brief case series report

joanne conway<sup>1</sup>, anna gould<sup>1</sup>, richard westley<sup>1</sup>, suneil raju<sup>1</sup>, anja oklopčic<sup>1</sup>, alex broadbent<sup>1</sup>, and Ahmed Hafiz<sup>1</sup>

<sup>1</sup>Affiliation not available

May 5, 2020

## Abstract

**Objectives:** In December 2019, a pneumonia like illness was first reported in Wuhan-China caused by a new coronavirus named corona virus disease -2019 (COVID-19) which then spread to cause a global pandemic. Most of the available data in the literature is derived from Chinese cohorts and we aim to contribute the clinical experience of a single British clinical centre with the characteristics of a British cohort. **Design:** A prospective case series. **Setting:** A single clinical centre in the UK. **Methods:** We have collected the demographics and medical characteristics of all COVID-19 positive cases admitted over two-week period. All cases were diagnosed by PCR. **Results:** Total of 71 COVID-19 patients were included in this case series. Majority of patients (75%) were [?]75 years old and 58% were men. Pre-existing comorbidities was common (85% of patients). Most patients presented with respiratory symptoms such as fever (59%), shortness of breath (56%) and cough (55%). Gastrointestinal symptoms were second most common presenting complaint such as diarrhoea (10%) and abdominal pain (7%). Opacification in chest X-rays were demonstrated in 45% of patients. All patients received supportive treatment and no specific antiviral therapy was administered in this cohort. So far, 18 (25%) patients have fully recovered, 9 patients (13%) escalated to a higher level of care and 10 (14%) have died. Patients who died were non-significantly older than those who have recovered (78.0 v 69.2 years,  $p=0.15$ ) but they had a significantly higher clinical frailty scores (5.75 v 3.36,  $p=0.005$ ). **Conclusion:** This case series demonstrated that the characteristics of British COVID-19 patients were generally similar to what is published in literature although we report more gastrointestinal symptoms at presentation. We have identified frailty as a risk factor for adverse outcome in COVID-19 patients and suggest that it should be included in the future vaccination recommendations.

## Introduction

The respiratory disease COVID-19 was initially reported in Wuhan-Hubei province-China. <sup>1</sup> The disease has since become a global pandemic. COVID-19 spreads rapidly by human-to-human transmission, primarily through respiratory droplets, physical contact and via fomites. <sup>2</sup> Compared with influenza, COVID-19 is thought to have a higher reproductive number of 2-2.5 (more people will be infected per index case) but a longer serial interval of 5-6 days (compared with 3 days for influenza). <sup>3</sup> COVID-19 typically presents with fever, myalgia, fatigue and dyspnoea or with less common gastrointestinal symptoms and headache. <sup>2</sup> Chest imaging shows bilateral patchy shadows, and blood tests often reveal lymphopaenia. <sup>4</sup> A fatality rate of 2.3% across all age groups, 14.8% in patients [?]80 years old and 8.0% in those 70-79 of age has been reported. <sup>5</sup> Mortality was found to be higher in patients with pre-existing comorbidities.<sup>5</sup> Most of the available data in the literature is derived from Chinese cohorts of patients. The objective of this case series is to collect clinical data on patients' characteristics, clinical presentations, laboratory findings, and progression of patients admitted to a District General Hospital in the UK with confirmed COVID-19 tests. Our aim is to contribute the clinical experience of a single British clinical centre to the rapidly growing

global data pool on this new life-threatening respiratory disease.

## Methods

### Design

A prospective case series.

### Setting

District general hospital in UK. Patients are first admitted into acute medical unit (AMU) which accepts non-selective cases with acute medical conditions. The unit is open to other specialties input, if required, including access to intensive care unit (ICU) for severely ill patients. As a routine practice, a Do Not Attempt Resuscitation (DNAR) form is usually signed by a senior medical officer after discussion with the patients and their families.

### Case definition

We have included all the COVID-19 confirmed cases admitted over 2-week period from 23<sup>rd</sup> March to 4<sup>th</sup> April 2020. Initial screening for cases was undertaken in line with Public Health England (PHE) which identifies suspected case as those presenting with clinical or radiological evidence of pneumonia, fever and respiratory symptoms. <sup>6</sup>

### Case confirmation

Patients meeting the above criteria then had nasopharyngeal and oropharyngeal swabs for identification of 2019-nCoV nucleic acid by reverse transcription polymerase chain reaction (RT-PCR). Patients who tested negative by RT-PCR but still have a high index of clinical suspicion were re-tested with a further swab for RT-PCR. All suspected patients had an initial chest X-ray, some had a CT scan based on clinical requirement. CT scan was not used as a diagnostic tool and all of the patients had a RT-PCR confirmed diagnosis.

### Data collection

We identified all COVID-19 cases from our laboratory data-base which has been followed up on a daily basis. Medical records were reviewed and patients' demographic, medical and social history was collected. Laboratory and radiological information were available in the electronic records. We used a standardised data collection sheet which was used by all the authors. To assess frailty, we used the clinical frailty score (CFS) which classify patients in a range of very fit (score 1) to terminally ill (score 9). <sup>7</sup>

### Statistical analysis

Continuous variables are presented as means and standard deviations (SD) and categorical ones as percentages. The t-test was used for continuous variables and two-sided p value of <0.05 was considered significant. We displayed descriptive statistics using the statistical software package StataCorp. 2019. Stata Statistical Software: Release 16. College Station, TX: StataCorp LLC.

## Results

Total of 71 COVID-19 confirmed consecutive cases who were admitted to hospital over 2 week period were included. Patient demographics are displayed in Table 1. Majority (75%) of patients were ≥65 years old, 58% were men and the source of infection was unidentified in the majority of cases (77%). Likely the transmission was human to human as no animal contact was recorded. Five patients reported that they had contact with a symptomatic family member, 3 returned to the UK from a holiday (2 from Spain and 1 from a Mediterranean cruise). Eight patients were admitted for other medical conditions and developed symptoms and tested positive while in-hospital. Most of the patients (85%) had pre-existing comorbidities, with hypertension (45%) most common, followed by cardiovascular disease (34%), chronic obstructive pulmonary disease (33%) and diabetes (23%). Presenting symptoms and clinical observations on the day of admission are displayed in Table 2. Respiratory symptoms were the most common presenting complaint such as fever (59% of patients), shortness of breath (56%) and cough (55%). Gastrointestinal symptoms were the second most

common such as diarrhoea (10%) and abdominal pain (7%). Most patients (66%) were hypoxic and required oxygen therapy on admission. Initial laboratory results and imaging are displayed in Table 3. Leucocytosis associated with lymphopenia was the most common laboratory abnormality. Opacifications in chest X-rays were demonstrated in 32 patients. Seven patients had a CT-chest due to worsening of their condition. All of the CT scans demonstrated ground glass changes. All patients received supportive treatment but no specific antiviral therapy was administered. Available outcome data is displayed in Table 4. Patients who died ranged from 66-90 years old and were none significantly older than those who have recovered and been discharged (average age 78.0 v 69.2 years,  $p=0.15$ ) but they had a significantly higher clinical frailty scores (5.75 v 3.36,  $p=0.005$ ).

## Discussion

We present the first UK clinical data of 71 cases of COVID-19 patients admitted to one clinical centre. The majority of patients (70 patients) were white British and one patient was Asian. Our cohort of patients of mean (SD) age of 70.7 (16.6) years, with 75% are  $\geq 65$  years, appears older than the published Chinese cohort {median age was only 46.0 years and the proportion of older patients ( $> 60$  years) was 44.1%}, we had slightly more men (58% v 51.6%) but the comorbidities were similar.<sup>8</sup> Around 10% of our patients presented with gastrointestinal symptoms such as diarrhoea compared to only 3.8% in a Chinese study.<sup>9</sup> Although in another Chinese study by Wang et al, 10% of patients initially presented with nausea and diarrhoea 1-2 days before the onset of fever and dyspnoea.<sup>4</sup> Laboratory systemic abnormalities particularly lymphopenia and elevated CRP and chest imaging findings are consistent with previously published literature.<sup>10</sup> The majority of our patients (55%) had normal chest x-ray in comparison to only around 18% in a Chinese report.<sup>9</sup> Our case fatality rate of 14% was similar to 8% for those aged 70-79 and 14.8% for those  $\geq 80$  years that was reported from China.<sup>8</sup> Also, previously, older age has been reported as an important independent predictor of mortality in SARS and MERS.<sup>11, 12</sup> Older people are more susceptible to infection likely due to associated comorbidities and attenuation of the innate immunity.<sup>13</sup> The ageing immune system is characterized by a low grade and chronic systemic inflammatory state or “InflammAgeing” and is associated with an increased susceptibility to infection.<sup>14</sup> One important finding in this case series, which has not been reported yet in the literature, is the emergence of frailty as a detrimental significant factor for poor outcome in patients with COVID-19. Frailty is a syndrome that is characterised by multisystem dysregulation that leads to reduced physiologic reserve and increased risk of adverse health outcomes. Dysregulation in the innate and adaptive immunity also leads to chronic inflammation, with increase in inflammatory markers, and increased susceptibility to severe infections. Increased inflammatory markers have been shown in patients with viral pneumonia.<sup>13</sup> Although frailty was not formally assessed in the COVID-19 studies, the fact that old age is associated with comorbidities and was associated with an increased risk of COVID-19 infection and worse outcomes may suggest underlying frailty was common in these old patients. The strength of this case series is its prospective design which allowed follow up of cases as well as the use of electronic record which allowed accurate documentation of results. However, this study has few limitations which include first, the small number included so far and the incomplete conclusion of outcomes of the patients who are still under treatment in hospital however, this series is in a continuous follow up and successive publications will follow as more information are gathered. Second, we were not able to record the incubation period for the current infection as this was not clearly re-called by the patients. Third, we are not able to report efficacy of any specific antiviral therapy as per our hospital protocol, this has not been used.

## Conclusion

This case series demonstrated that the characteristics of British COVID-19 patients were generally similar to what is published so far in literature although we report more gastrointestinal symptoms at presentation and more normal chest X-ray findings in our cohort. We have also identified frailty as an emergent risk factor for adverse outcome in COVID-19 patients and suggest that it should be included in the future vaccination recommendations.

## References

- 1) Li Q, Guan X, Wu P, et al. Early Transmission Dynamics in Wuhan, China, of Novel Coronavirus-Infected Pneumonia. *NEJM* 2020; 382: 1199-207.
2. COVID-19: epidemiology, virology and clinical features. GOV.UK. 2020 [Date of Access: 8 April 2020]. URL: <https://www.gov.uk/government/publications/wuhan-novel-coronavirus-background-information/wuhan-novel-coronavirus-epidemiology-virology-and-clinical-features>.
3. Q&A: Similarities and differences – COVID-19 and influenza. World Health Organization 2020 [Date of Access: 8 April 2020]. URL: <https://www.who.int/news-room/q-a-detail/q-a-similarities-and-differences-covid-19-and-influenza>
4. Wang D, Hu B, Hu C, et al. Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA* 2020; 323: 1061. URL: <https://www.ncbi.nlm.nih.gov/pubmed/32031570>.
5. Wu Z, McGoogan J. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19) Outbreak in China. *JAMA* 2020; 323: 1239. Available from: <https://jamanetwork.com/journals/jama/fullarticle/2762130>.
6. COVID-19: investigation and initial clinical management of possible cases [Internet]. GOV.UK. 2020 [cited 8 April 2020]. Available from: <https://www.gov.uk/government/publications/wuhan-novel-coronavirus-initial-investigation-of-possible-cases/investigation-and-initial-clinical-management-of-possible-cases-of-wuhan-novel-coronavirus-wn-cov-infection>
7. K. Rockwood et al. A global clinical measure of fitness and frailty in elderly people. *CMAJ* 2005; 173: 489-95.
8. The novel coronavirus pneumonia emergency response epidemiology team. The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) —China, 2020. *China CDC Weekly*. 2020; 2: 113-22.
9. Guan W, Ni Z, HU Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. *NEJM* 2020; DOI: 10.1056/NEJMoa2002032.
10. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* 2020; 395: 497-506.
11. Choi KW, Chau TN, Tsang O, et al. Outcomes and prognostic factors in 267 patients with severe acute respiratory syndrome in Hong Kong. *Ann Intern Med* 2003; 139: 715-23.
12. Hong K-H, Choi J-P, Hong S-H, et al. Predictors of mortality in Middle East respiratory syndrome (MERS). *Thorax* 2018; 73: 286-9.
13. Guo L, Wei D, Zhang X, et al. Clinical Features Predicting Mortality Risk in Patients With Viral Pneumonia: The MuLBSTA Score. *Front Microbiol* 2019; 10: 2752.
14. Franceschi C, Bonafe M, Valensin S, et al. Inflamm-aging. An evolutionary perspective on immunosenescence. *Ann N Y Acad Sci* 2000; 908: 244-54.

| <b>Table 1: Patients Demographics.</b> |
|--|--|--|--|
| <b>Personal Demographics</b>           |  | <b>Total number</b>                    | 71                                     |
|  | <b>Age (years)</b>                     | Mean (SD)                              | 70.                                    |
|  |  | 18-64                                  | 18                                     |
|  |  | 65+                                    | 53                                     |
|  |  | Range                                  | 24-                                    |
|  | <b>Sex</b>                             | Male                                   | 41                                     |
|  | <b>Race</b>                            | White British                          | 70                                     |

Table 1: Patients Demographics.	Table 1: Patients Demographics.	Table 1: Patients Demographics.	Number of Patients
	<b>CFS</b>	Asian	1 (1.4)
		Mean (SD)	4.1 (1.1)
		<5	42 (51.2)
		5+	29 (35.4)
	<b>Source</b>	Unknown	55 (66.9)
		Hospital acquired	8 (9.8)
		Family member	5 (6.1)
		Recent travel	3 (3.7)
	<b>Pre-existing conditions</b>	Any	60 (72.9)
		HTN	32 (39.3)
		CVD	24 (29.3)
		COPD	23 (28.1)
		DM	16 (19.5)
		Dementia	10 (12.3)
		Renal disease	9 (10.9)
		Liver disease	5 (6.1)
	<b>Smoking status</b>	Unknown	38 (46.3)
		Ex-smoker	20 (24.4)
		Never smoked	13 (15.8)
		Current smoker	0 (0)

CFS=Clinical frailty score, HTN=Hypertension, DM=Diabetes mellitus,  
 COPD=Chronic obstructive pulmonary disease, CVD=Cardiovascular disease.

Table 2: Presenting symptoms and initial observations.	Table 2: Presenting symptoms and initial observations.	Table 2: Presenting symptoms and initial observations.	Number of Patients (%)
<b>Clinical Presentation</b>	<b>Symptoms</b>	Fever	42 (59)
		SOB	40 (56)
		Cough	39 (55)
		Fatigue	16 (23)
		Phlegm	9 (12.6)
		Vomiting	8 (11)
		New confusion	8 (11)
		Diarrhoea	7 (9.8)
		Generally unwell	7 (9.8)
		Myalgia	6 (8.5)
		Abdominal pain	5 (7)
		Headache	4 (5.6)
		Chest pain	4 (5.6)
		Sore Throat	2 (2.8)
		Fall	2 (2.8)
		Collapse	2 (2.8)
		Anosmia	2 (2.8)
		Poor oral intake	1 (1.4)
		Haemoptysis	1 (1.4)
		Change in taste	1 (1.4)

Table 2: Presenting symptoms and initial observations.	Table 2: Presenting symptoms and initial observations.	Table 2: Presenting symptoms and initial observations.	Number of Patients (%)
Initial Observations	Temperature (Celsius)	<37.5	29 (41)
		37.5+	42 (59)
	Oxygen Sats	<96%	47 (66)
		96%+	24 (34)
	RR	<20	18 (25)
		20+	53 (75)
	Systolic BP (mmHg)	<120	21 (29.5)
		120+	50 (70.5)
HR	<100	48 (67.7)	
	100+	23 (32.3)	

SOB=Shortness of breath, RR=Respiratory rate, Sats=Saturation, BP=Blood pressure, HR=Heart rate.

Table 3: Lab results and imaging.	Table 3: Lab results and imaging.	Table 3: Lab results and imaging.
Investigations	Blood results	Total WCC Neutrophil Lymphocyte Eosinophil Hb Creatinine Urea Na <sup>+</sup> K <sup>+</sup> ALT AST CRP
	Chest-XR	Clear Unilateral consolidation B/L consolidation CT chest

WCC=White cell count, Hb=Haemoglobin, ALT=Alanine aminotransferase, AST=Aspartate aminotransferase, CRP=C-reactive protein, XR=X-Ray, CT=Computerised tomography, B/L=Bilateral.

Table 4: Patients outcomes	Table 4: Patients outcomes	Outcomes	Outcomes	Outcomes
Average	Number (%)	Home	HDU/ICU	Death
	Age (years)	18 (25)	9 (13)	10 (14)
	Clinical frailty score*	69.2	61.2	78
	Total WCC	3.36	2.56	5.75
	Neutrophil	8.89	9.28	5.46
	Lymphocytes	7.26	8.1	4.33
		0.87	0.73	0.58
	Outcomes (%)	Outcomes (%)	Outcomes (%)	Outcomes (%)

		<b>Outcomes</b>	<b>Outcomes</b>	<b>Outcomes</b>
		<b>Home</b>	<b>HDU/ITU</b>	<b>Death</b>
<b>Number of patients</b>	<b>No co-morbidities</b>	4 (22)	4 (44)	0
	<b>Any co-morbidities</b>	14 (78)	5 (56)	10 (100)
	<b>Any XR findings</b>	15 (21)	9 (100)	6 (60)
	<b>Normal XR</b>	3 (17)	0	4 (40)
	<b>Needed oxygen</b>	11 (61)	7 (78)	6 (60)

HDU/ICU=High-dependency unit/intensive care unit, \*significant.